Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $495.09 | 13 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $495.09 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $369.71 | 12 | ABBVIE INC. ($369.71) |
| 2023 | $125.38 | 1 | ABBVIE INC. ($125.38) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE | Food and Beverage | In-kind items and services | $11.62 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/25/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $108.87 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/10/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/23/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/04/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/26/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $10.73 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/12/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/29/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $10.82 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/15/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/22/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/31/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $116.41 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/04/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $125.38 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 861 | 3,146 | $615,360 | $219,213 |
| 2022 | 3 | 984 | 3,484 | $727,356 | $210,510 |
| 2021 | 2 | 1,128 | 4,326 | $900,171 | $264,606 |
| 2020 | 2 | 1,325 | 4,826 | $952,644 | $310,632 |
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 412 | 2,630 | $483,920 | $154,343 | 31.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 423 | 490 | $122,600 | $62,350 | 50.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 26 | $8,840 | $2,520 | 28.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 498 | 2,898 | $533,232 | $151,986 | 28.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 436 | 529 | $179,860 | $50,112 | 27.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 50 | 57 | $14,264 | $8,413 | 59.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 567 | 3,655 | $672,337 | $197,710 | 29.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 561 | 671 | $227,834 | $66,896 | 29.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 653 | 4,009 | $699,869 | $224,255 | 32.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 672 | 817 | $252,775 | $86,377 | 34.2% |
About Dr. Muhammad Iqbal, MD
Dr. Muhammad Iqbal, MD is a Infectious Disease healthcare provider based in New Berlin, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417039124.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Iqbal, MD has received a total of $495.09 in payments from pharmaceutical and medical device companies, with $369.71 received in 2024. These payments were reported across 13 transactions from 1 company. The most common payment nature is "Food and Beverage" ($495.09).
As a Medicare-enrolled provider, Iqbal has provided services to 4,298 Medicare beneficiaries, totaling 15,782 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location New Berlin, WI
- Active Since 10/20/2006
- Last Updated 11/14/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1417039124
Products in Payments
- TEFLARO (Drug) $214.42
- DALVANCE (Drug) $143.67
- AVYCAZ (Drug) $137.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.